Though efficacy of Allergen Specific Immunotherapy (ASIT) has been proved in many studies, reports about success in clinical practice and under field conditions in alleviating the suffering or decreasing the morbidity...Though efficacy of Allergen Specific Immunotherapy (ASIT) has been proved in many studies, reports about success in clinical practice and under field conditions in alleviating the suffering or decreasing the morbidity in patients of Allergic Rhinitis are few. 260 patients of Allergic Rhinitis without coexisting diseases were included. Skin prick test was done on all patients. ASIT was initiated with common inhalant indoor allergens as per standard protocol and patients were assessed at the start and at 2 m, 6 m and 18 months of ASIT. ASIT was able to significantly reduce the symptom score in all the three groups namely sneezing, rhinorrhoea and nasal itching (p < 0.001). Concurrently it was also able to produce a significant reduction in the usage of concomitant drug intake (p < 0.001) thereby implying a decrease in morbidity. When assessed regarding clinical efficacy, ASIT was found to be satisfactory or highly effective in more than 75% patients. ASIT has got a role in clinical practice in polysensitized patients in field conditions. This is based on the evidence that besides decrease in hypersensitivity/symptoms, it also has an effect on minimizing the necessity of taking drugs to relieve the symptoms, which has strong implications of economics and toxicity, while treating patients.展开更多
The prevention,early discovery and effective treatment of patients with hepatocellular carcinoma(HCC)remain a global medical challenge.At present,HCC is still mainly treated by surgery,supplemented by vascular emboliz...The prevention,early discovery and effective treatment of patients with hepatocellular carcinoma(HCC)remain a global medical challenge.At present,HCC is still mainly treated by surgery,supplemented by vascular embolization,radio frequency,radiotherapy,chemotherapy and biotherapy.The application of multikinase inhibitor sorafenib,chimeric antigen receptor T cells,or PD-1/PD-L1 inhibitors can prolong the median survival of HCC patients.However,the treatment efficacy is still unsatisfactory due to HCC metastasis and postoperative recurrence.During the process of hepatocyte malignant transformation,HCC tissues can express and secrete many types of specific biomarkers,or oncogenic antigen molecules into blood,for example,alpha-fetoprotein,glypican-3,Wnt3a(one of the key signaling molecules in the Wnt/β-catenin pathway),insulin-like growth factor(IGF)-II or IGF-I receptor,vascular endothelial growth factor,secretory clusterin and so on.In addition,combining immunotherapy with noncoding RNAs might improve anti-cancer efficacy.These biomarkers not only contribute to HCC diagnosis or prognosis,but may also become molecular targets for HCC therapy under developing or clinical trials.This article reviews the progress in emerging biomarkers in basic research or clinical trials for HCC immunotherapy.展开更多
目的：本研究通过观察对室尘螨（HDM）过敏的儿童哮喘患者,过敏原特异性免疫治疗（allergen specific immunotherapy, SIT）后外周血CD4＋CD25＋CD127-Treg细胞（regulatory T cell, Treg）细胞）占CD4＋T cell的百分比的变化,以及它们...目的：本研究通过观察对室尘螨（HDM）过敏的儿童哮喘患者,过敏原特异性免疫治疗（allergen specific immunotherapy, SIT）后外周血CD4＋CD25＋CD127-Treg细胞（regulatory T cell, Treg）细胞）占CD4＋T cell的百分比的变化,以及它们在SIT治疗中的作用,初步探讨儿童过敏性哮喘SIT的机制,从而为哮喘的防治提供新思路。方法选取郑州大学第一附属医院儿科门诊48例儿童过敏性哮喘患者分两组,一组进行标准化SIT 1.5-2年后,采集两组患者的外周静脉血。用流式细胞仪检测每组标本中CD4＋CD25＋CD127-T细胞占CD4＋T细胞的百分比,结果采用统计学软件进行统计学分析。结果CD4＋CD25＋CD127-T细胞占CD4＋T细胞的百分比在HDM-SIT组显著增高。结论本实验进一步证实了哮喘患者SIT治疗有效；在HDM-SIT组CD4＋CD25＋CD127-T细胞占CD4＋T细胞的百分比升高,提示CD4＋CD25＋CD127-T细胞可能在儿童过敏性哮喘特异性免疫治疗中起重要作用。展开更多
文摘Though efficacy of Allergen Specific Immunotherapy (ASIT) has been proved in many studies, reports about success in clinical practice and under field conditions in alleviating the suffering or decreasing the morbidity in patients of Allergic Rhinitis are few. 260 patients of Allergic Rhinitis without coexisting diseases were included. Skin prick test was done on all patients. ASIT was initiated with common inhalant indoor allergens as per standard protocol and patients were assessed at the start and at 2 m, 6 m and 18 months of ASIT. ASIT was able to significantly reduce the symptom score in all the three groups namely sneezing, rhinorrhoea and nasal itching (p < 0.001). Concurrently it was also able to produce a significant reduction in the usage of concomitant drug intake (p < 0.001) thereby implying a decrease in morbidity. When assessed regarding clinical efficacy, ASIT was found to be satisfactory or highly effective in more than 75% patients. ASIT has got a role in clinical practice in polysensitized patients in field conditions. This is based on the evidence that besides decrease in hypersensitivity/symptoms, it also has an effect on minimizing the necessity of taking drugs to relieve the symptoms, which has strong implications of economics and toxicity, while treating patients.
基金Supported by the National Natural Science Foundation of China,No. 84673241, No. 81873915 and No. 31872738Nantong S&T Development Plan,No. MS12020021, and No. MS12019016
文摘The prevention,early discovery and effective treatment of patients with hepatocellular carcinoma(HCC)remain a global medical challenge.At present,HCC is still mainly treated by surgery,supplemented by vascular embolization,radio frequency,radiotherapy,chemotherapy and biotherapy.The application of multikinase inhibitor sorafenib,chimeric antigen receptor T cells,or PD-1/PD-L1 inhibitors can prolong the median survival of HCC patients.However,the treatment efficacy is still unsatisfactory due to HCC metastasis and postoperative recurrence.During the process of hepatocyte malignant transformation,HCC tissues can express and secrete many types of specific biomarkers,or oncogenic antigen molecules into blood,for example,alpha-fetoprotein,glypican-3,Wnt3a(one of the key signaling molecules in the Wnt/β-catenin pathway),insulin-like growth factor(IGF)-II or IGF-I receptor,vascular endothelial growth factor,secretory clusterin and so on.In addition,combining immunotherapy with noncoding RNAs might improve anti-cancer efficacy.These biomarkers not only contribute to HCC diagnosis or prognosis,but may also become molecular targets for HCC therapy under developing or clinical trials.This article reviews the progress in emerging biomarkers in basic research or clinical trials for HCC immunotherapy.
文摘目的：本研究通过观察对室尘螨（HDM）过敏的儿童哮喘患者,过敏原特异性免疫治疗（allergen specific immunotherapy, SIT）后外周血CD4＋CD25＋CD127-Treg细胞（regulatory T cell, Treg）细胞）占CD4＋T cell的百分比的变化,以及它们在SIT治疗中的作用,初步探讨儿童过敏性哮喘SIT的机制,从而为哮喘的防治提供新思路。方法选取郑州大学第一附属医院儿科门诊48例儿童过敏性哮喘患者分两组,一组进行标准化SIT 1.5-2年后,采集两组患者的外周静脉血。用流式细胞仪检测每组标本中CD4＋CD25＋CD127-T细胞占CD4＋T细胞的百分比,结果采用统计学软件进行统计学分析。结果CD4＋CD25＋CD127-T细胞占CD4＋T细胞的百分比在HDM-SIT组显著增高。结论本实验进一步证实了哮喘患者SIT治疗有效；在HDM-SIT组CD4＋CD25＋CD127-T细胞占CD4＋T细胞的百分比升高,提示CD4＋CD25＋CD127-T细胞可能在儿童过敏性哮喘特异性免疫治疗中起重要作用。
